Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
Allosteric modulation of the dopamine D2 receptor: Implications for the treatment of schizophrenia
FY 2011-12
Summary
Schizophrenia is a serious mental disorder that affects over 330,000 people in Canada, for which there is no adequate treatment. This mental illness manifests in various ways, and is often characterized by the appearance of positive symptoms (hallucinations, disorganized behaviour), negative symptoms (alogia, avolition, attention impairment) and cognitive dysfunction (memory impairment, attention deficit, and disturbances in executive function). Current treatment methodologies involve blocking or activating the dopamine receptor by binding to the same site as the neurochemical dopamine. These treatments do no remedy all symptoms of the disorder and lead to an array of adverse side effects, which can include weight gain, diabetes, and various movement disorders. Evidently, there is a strong demand for a new generation of antipsychotic drugs to effectively treat mental disorders while avoiding the adverse effects associated with current therapeutics. Allosteric drugs are evolving as a new wave of treatment with promising implications for various neuropsychiatric disorders. We have developed a novel allosteric drug, PAOPA, which offers a number of distinct advantages over conventional treatments. PAOPA binds to an alternative site on the dopamine D2 receptor, has selective specificity for the D2 receptor subtype, and is devoid of activity in the absence of bound dopamine. PAOPA has been shown to prevent and treat schizophrenia-like pathological symptoms in preclinical animal models of schizophrenia with no adverse effects. The studies outlined in this proposal will categorize the therapeutic potential of PAOPA as well as investigate its mechanism of action in preventing and reversing behavioural abnormalities in pre-clinical models of the disorder. These studies aim to develop PAOPA into a new generation of antipsychotic drug as well as set the foundation for the development of allosteric drugs to treat schizophrenia and other related mental disorders.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
253336
Name
Daya Ritesh
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Allosteric modulation of the dopamine D2 receptor: Implications for the treatment of schizophrenia
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Allosteric Modulation; Dopamine D2 Receptor; High-Performance Liquid Chromatography; Hypofrontality; In Vivo Microdialysis; Pet-Ct Fused Imaging; Pre-Clinical Animal Models Of Schizophrenia; Schizophrenia
Abstract
Schizophrenia is a serious mental disorder that affects over 330,000 people in Canada, for which there is no adequate treatment. This mental illness manifests in various ways, and is often characterized by the appearance of positive symptoms (hallucinations, disorganized behaviour), negative symptoms (alogia, avolition, attention impairment) and cognitive dysfunction (memory impairment, attention deficit, and disturbances in executive function). Current treatment methodologies involve blocking or activating the dopamine receptor by binding to the same site as the neurochemical dopamine. These treatments do no remedy all symptoms of the disorder and lead to an array of adverse side effects, which can include weight gain, diabetes, and various movement disorders. Evidently, there is a strong demand for a new generation of antipsychotic drugs to effectively treat mental disorders while avoiding the adverse effects associated with current therapeutics. Allosteric drugs are evolving as a new wave of treatment with promising implications for various neuropsychiatric disorders. We have developed a novel allosteric drug, PAOPA, which offers a number of distinct advantages over conventional treatments. PAOPA binds to an alternative site on the dopamine D2 receptor, has selective specificity for the D2 receptor subtype, and is devoid of activity in the absence of bound dopamine. PAOPA has been shown to prevent and treat schizophrenia-like pathological symptoms in preclinical animal models of schizophrenia with no adverse effects. The studies outlined in this proposal will categorize the therapeutic potential of PAOPA as well as investigate its mechanism of action in preventing and reversing behavioural abnormalities in pre-clinical models of the disorder. These studies aim to develop PAOPA into a new generation of antipsychotic drug as well as set the foundation for the development of allosteric drugs to treat schizophrenia and other related mental disorders.
Competitiondate
201202
Approvedterm2
1 yr 0 mth
Pinamesdelim
Daya, Ritesh
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~